1311275-35-0

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
6-bromo-2,4-dichlorothieno[3,2-d]pyrimidine is utilized as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure allows it to interact with biological targets, modulating their activity and contributing to the development of new therapeutic agents and crop protection products.
Used in Medicinal Chemistry and Drug Discovery:
In the field of medicinal chemistry, 6-bromo-2,4-dichlorothieno[3,2-d]pyrimidine is employed as a building block for the design and synthesis of novel compounds with potential therapeutic applications. Its ability to modulate the activity of biological targets makes it a promising candidate for the development of new drugs targeting various diseases and conditions.
Used in Pesticide or Herbicide Development:
6-bromo-2,4-dichlorothieno[3,2-d]pyrimidine has been studied for its potential use as a pesticide or herbicide. Its unique chemical structure and ability to interact with biological targets make it a candidate for the development of new and effective crop protection agents, helping to improve agricultural productivity and crop protection.

Upstream product

• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 860354-58-1 methyl 5-bromo-3-({[(trichloroacetyl)amino]carbonyl}amino)thiophene-2-carboxylate 
• 860354-59-2 3-[(aminocarbonyl)amino]-5-bromo-2-thiophenecarboxylic acid methyl ester 
• 1388027-23-3 6-bromothieno[3,2-d]pyrimidine-2,4-diol 
• 860354-57-0 methyl 3-({[(trichloroacetyl)amino]carbonyl}amino)thiophene-2-carboxylate 
• 107818-55-3 3-amino-5-bromo-thiophene-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Discovery of an Orally Active and Long-Acting DPP-IV Inhibitor through Property-Based Optimization with an in Silico Biotransformation Prediction Tool

Long-acting dipeptidyl peptidase IV inhibitors have emerged as promising molecules for interventions for type 2 diabetes. Once weekly dosing brings greater patient compliance and more stable glycemic control. Starting from our previous highly potent compound with a thienoprimidine scaffold, which is unfortunately severely hit by hepatic biotransformation, a lead compound was rapidly generated by drawing on the experience of our previously discovered long-acting compounds with pyrrolopyrimidine scaffold. With the aid of an in silico biotransformation prediction tool, (R)-2-((2-(3-aminopiperidin-1-yl)-4-oxo-6-(pyridin-3-yl)thieno[3,2-d]pyrimidin-3(4H)-yl)methyl)-4-fluorobenzonitrile was eventually generated and determined to have high potency, a fine pharmacokinetic profile, and a long-acting in vivo efficacy.

Thienopyrimidinone compound or pharmaceutically-acceptable salt thereof and preparation method and application thereof

The invention provides a thienopyrimidinone compound or pharmaceutically-acceptable salt thereof and a preparation method and application thereof. The thienopyrimidinone compound or the pharmaceutically-acceptable salt thereof has a novel chemical structure, it is verified through in-vitro and in-vivo experiments that a very good selective inhibiting effect on DPP-IV is achieved, the activity of DPP-VIII and DPP-IX is barely affected while the activity of DPP-IV is effectively inhibited, meanwhile, the inhibition ratio of a potassium ion channel is low, and it can be predicted that the toxicity is low after the compound is developed into medicine. Compared with medicine trelagliptin orally taken once every week on the market, the thienopyrimidinone compound has fairly high or higher bioavailable efficiency, it can be predicted that after the compound is developed, the treatment effect that the compound is orally taken once for a long time, and the convenience and compliance of a patient are greatly improved. The preparation method is simple, the raw materials are easy to obtain, and the preparation method is suitable for industrial large-scale production.

2,4-Diaminothienopyrimidines as orally active antimalarial agents

A novel series of 2,4-diaminothienopyrimidines with potential as antimalarials was identified from whole-cell high-throughput screening of a SoftFocus ion channel library. Synthesis and structure-activity relationship studies identified compounds with potent antiplasmodial activity and low in vitro cytotoxicity. Several of these analogues exhibited in vivo activity in the Plasmodium berghei mouse model when administered orally. However, inhibition of the hERG potassium channel was identified as a liability for this series.